All Releases
SubscribeFolgen
Subscribe to Stada Arzneimittel
Keine Meldung Stada Arzneimittel mehr verpassen.

07.02.2020 – 10:34

Stada Arzneimittel

STADA to acquire established OTC and food supplement portfolio in the Philippines

STADA to acquire established OTC and food supplement portfolio in the Philippines
  • Photo Info
  • Download

One document

Press release

STADA to acquire established OTC and food supplement portfolio in the Philippines

- STADA's Philippines portfolio is strengthened with FERN C, a well-established 
  range of vitamin C food supplements.
- Sharmaine Abarientos, General Manager of STADA Philippines: "With FERN C in 
  our portfolio, we will establish a strong consumer healthcare platform to 
  launch other quality medicines as well and provide better health for all 
  Filipinos."
- STADA CEO Peter Goldschmidt: "The acquisition of FERN C will help us to 
  execute our growth ambitions in the Philippines." 

Bad Vilbel, February 7, 2020 - After announcing a number of acquisitions and partnerships in Europe recently, the STADA Group is also expanding its portfolio in the Asia-Pacific region. As the global manufacturer of high-quality generic drugs and consumer healthcare products announced today, STADA is acquiring the FERN C portfolio in the Philippines, one of the leading brands in the growing local vitamin C market. The product range consists of FERN C, a vitamin C product that has been in the market for 15 years, and two children's vitamin products - FERN C Kidz and Kiddimin.

STADA has a long lasting history of selling pharmaceutical products into the Philippines, formerly through Croma Medic Inc., which was recently renamed as STADA Philippines. "After having formally launched STADA Philippines, we are now fully enabled to execute our growth ambitions in this market as well. The acquisition of FERN C will help us to succeed. The acquisition of these products is in line with our strategy of strengthening our portfolio with well-established consumer healthcare brands and also expanding in selected emerging markets", states STADA CEO Peter Goldschmidt.

Sharmaine Abarientos, General Manager of STADA Philippines, adds: "FERN C has not only an established brand heritage, but also a complete range for adults as well as for the pediatric application. With FERN C in our portfolio, we will establish a strong consumer healthcare platform to launch other quality medicines as well and provide better health for all Filipinos. With our successful portfolio expansion activities, we are able to offer quality medicines at reasonable prices, across all segments of healthcare; specialty, generics and consumer health."

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel -
Germany 
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press  

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 
61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 
603-215 / E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations